Extended Data Fig. 1: Senolytic screen optimization.
From: cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis
a, Senescence-associated beta-galactosidase staining in one week of senescence inducers (0.5 µM Alisertib, 1 µM Barasertib, 50 nM CFI-400951 or 2 µM Etoposide) treated A549 and SK-Hep1 cells. The black scale bars present 100 µm. b, SENCAN classifier analysis18 on different senescence inducers treated A549 cells. c, Western blot analysis of P21 and phosp-RB in A549 treated with 50 nM CFI-400945 for 1 week. The result is representative of at least 3 repeats with similar results. d, Western blot analysis of CAS9 expression in A549-iCas9 clone on 24 hours treatment of 1 µg/ml doxycycline. The result is representative of at least 3 repeats with similar results. e, Incucyte growth curve on A549-iCas9 and the parental cells. f, A549 cells were infected with pXRP-011 and treated with or without 1 µg/ml doxycycline for a week. Afterwards, the GFP signals were measured by flow cytometry to determine gene editing efficiencies. (GFP depletion were checked at least 3 times with similar results). Error bars in this figure panel a, e represent as mean ± standard deviations, N = 3 independent experiments, statistical significance was calculated by two-tailed t-test.
